Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
EVALUATION OF THE SAFETY AND THE CLINICAL PERFORMANCE IN TREATMENT OF CHRONIC DIABETIC FOOT ULCER, WITH THE TROPOCELLS®, BASED AUTOLOGOUS PLATELET RICH FIBRIN (Tropocells(R) Autologous PRF Systems)
Sponsor: Estar Medical dba Medical Technologies, LTD
This PHASE2 trial investigates Chronic Wound Care and Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer) and is currently actively recruiting participants. Estar Medical dba Medical Technologies, LTD leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
3 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Estar Medical dba Medical Technologies, LTD
- WCG IRB
For direct contact, visit the study record on ClinicalTrials.gov .